USD
+$0.00
(+0.00%
)At Close (As of Oct 21, 2025)
$628.90M
Market Cap
-
P/E Ratio
-2.22
EPS
$24.17
52 Week High
$8.03
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $135M |
Total Revenue | $138M |
Cost Of Revenue | $3.5M |
Costof Goods And Services Sold | $3.5M |
Operating Income | -$96M |
Selling General And Administrative | $53M |
Research And Development | $195M |
Operating Expenses | $174M |
Investment Income Net | - |
Net Interest Income | $15M |
Interest Income | $15M |
Interest Expense | $0 |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $3.5M |
Income Before Tax | -$81M |
Income Tax Expense | -$4K |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$81M |
Comprehensive Income Net Of Tax | - |
Ebit | -$81M |
Ebitda | -$77M |
Net Income | -$81M |
Field | Value (USD) |
---|---|
Total Assets | $344M |
Total Current Assets | $306M |
Cash And Cash Equivalents At Carrying Value | $237M |
Cash And Short Term Investments | $237M |
Inventory | - |
Current Net Receivables | $4M |
Total Non Current Assets | $38M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | - |
Intangible Assets Excluding Goodwill | - |
Goodwill | - |
Investments | - |
Long Term Investments | - |
Short Term Investments | - |
Other Current Assets | $65M |
Other Non Current Assets | - |
Total Liabilities | $103M |
Total Current Liabilities | $65M |
Current Accounts Payable | $7.2M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $7.1M |
Total Non Current Liabilities | $38M |
Capital Lease Obligations | $29M |
Long Term Debt | - |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $29M |
Other Current Liabilities | $29M |
Other Non Current Liabilities | - |
Total Shareholder Equity | $241M |
Treasury Stock | - |
Retained Earnings | -$449M |
Common Stock | $27K |
Common Stock Shares Outstanding | $27M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$60M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $3.5M |
Capital Expenditures | $648K |
Change In Receivables | - |
Change In Inventory | - |
Profit Loss | - |
Cashflow From Investment | -$648K |
Cashflow From Financing | $5.4M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$81M |
Field | Value (USD) |
---|---|
Gross Profit | $135M |
Total Revenue | $138M |
Cost Of Revenue | $3.5M |
Costof Goods And Services Sold | $3.5M |
Operating Income | -$96M |
Selling General And Administrative | $53M |
Research And Development | $195M |
Operating Expenses | $174M |
Investment Income Net | - |
Net Interest Income | $15M |
Interest Income | $15M |
Interest Expense | $0 |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $3.5M |
Income Before Tax | -$81M |
Income Tax Expense | -$4K |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$81M |
Comprehensive Income Net Of Tax | - |
Ebit | -$81M |
Ebitda | -$77M |
Net Income | -$81M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Arcturus Therapeutics Holdings Inc. is a pioneering biopharmaceutical company based in San Diego, California, dedicated to the development of RNA-based therapeutics aimed at addressing critical unmet medical needs, particularly in liver and respiratory diseases. The company leverages its proprietary RNA delivery platform to advance a promising pipeline of innovative drug candidates, focusing on enhancing patient outcomes. With a strong emphasis on technological advancements and industry expertise, Arcturus is strategically positioned to capitalize on emerging opportunities in the biotechnology sector, making a significant impact on the future of healthcare.